Compare Hut 8 Corp (HUT) vs Neurocrine Biosciences Inc (NBIX) Price & Performance

Hut 8 CorpTrade

Neurocrine Biosciences IncTrade

Price performance (Past 24H)

Key statistics

Hut 8 Corp vs Neurocrine Biosciences Inc — how do they compare? Hut 8 Corp trades at $109.49 (market cap $11.36B), while Neurocrine Biosciences Inc trades at $179.88 (market cap $17.40B). The key difference: Neurocrine Biosciences Inc is the larger of the two by market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Hut 8 Corp nearer its low. Which is the better fit depends on your goals.

	HUT	NBIX
Market Cap	$11.36B	$17.40B
Sector	Technology	Health
52-Week High	$133.02	$180.55
52-Week Low	$19.45	$123.10
Enterprise Value	$11.63B	$16.49B

View details →View details →

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

HUT

Hut 8 Mining signs $9.8B lease, AMC beats Q2 estimates, Replenish Nutrients secures $15M investmentProactive Investors · 1 day agoBullish Hut 8 signs $9.8B lease to expand AI data center capacity, Needham raises price target to $145Tony Dante · 1 day agoBullish Hut 8 doubles AI data center lease capacity to 704 MW with $9.8B 15-year contract at Beacon Point campusPRNewsWire · 1 day agoBullish View details →

NBIX

Neurocrine Biosciences appoints Samir Siddhanti as Chief Business Officer to lead growth strategy.PRNewsWire · 5 hours agoBullish View details →

About Hut 8 Corp

Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.

About Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.